So you have a new link and updated cost, or should we just take your word for it? Also, what is the cost to Advent because they subtract all costs and then add in a 15% guaranteed profit before NWBO and UCLA share what is left over. ?
Also, are you saying the potential revenues were cut in half? How will they ever make money that way in the tiny UK market?
Sentiment, That is a smart, win-win pricing model for DCVax-L. Year 1 at under-$100K (mfg, 6 doses), year 2 at ~$40K(2 booster doses), and so on, until all doses are used up, not only sounds smart but sounds like: - it communicates (to patients, hospitals, and insurance companies) the “immune durability” aspect - that the subsequent payments are tied to "the curing” of the cancer - and there is a potential continuing revenue model aspect to this.
So to say that is a win-win pricing model is probably an understatement.
Just to show contrast, consider that “2 previous meta-analyses demonstrated that novel cancer drugs only marginally extend life by 2 to 3 months on average.” https://ascopubs.org/doi/full/10.1200/JCO.22.00535l and that most novel new cancer drugs cost ~$200K per year, emphasize “each year”.
I also think there is a strategic marketing component built into this pricing model that is designed for market penetration. - DCVax’s broad cancer vaccine benefits and tumor agnostic profile, give it a price elasticity advantage. - Flaskworks gives it an economies of scale advantage. - The cheaper it is, the more rapid the expansion DCVax will have into other cancer markets - and as I see it, DCVax becomes a base-layer therapy for all cancers in the future.
Market Data 
Markets 
